These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 29303368)

  • 21. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
    Cools J
    Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
    Gotlib J; Cools J; Malone JM; Schrier SL; Gilliland DG; Coutré SE
    Blood; 2004 Apr; 103(8):2879-91. PubMed ID: 15070659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of FIP1L1-PDGFRA fusion gene-positive cells in the skin lesion of a patient with hypereosinophilic syndrome.
    Kitayama S; Makino T; Yoto A; Mori S; Furukawa F; Torai R; Mizawa M; Shimizu T
    Clin Exp Dermatol; 2023 Mar; 48(4):364-367. PubMed ID: 36763740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
    Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
    Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
    Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A
    Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
    Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
    Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome.
    Helbig G; Hus M; Hałasz M; Dudziński M; Więcławek A; Stachowicz M; Soja A; Kyrcz-Krzemień S
    Med Oncol; 2012 Jun; 29(2):1073-6. PubMed ID: 21258876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New insights into hypereosinophilic syndromes].
    Bletry O; Kahn JE; Ackermann F; Charles P; Legrand F
    Bull Acad Natl Med; 2010 Mar; 194(3):547-59; discussion 559-60. PubMed ID: 21171248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.
    Yamada Y; Cancelas JA; Rothenberg ME
    Int Arch Allergy Immunol; 2009; 149 Suppl 1():102-7. PubMed ID: 19494514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficiency of imatinib in polyserositis revealing a FIP1L1-PDGFRA-negative hypereosinophilic syndrome].
    Green L; Kahn JE; Dufour JF; Le Scanff J; Charhon A; Broussolle C; Sève P
    Rev Med Interne; 2010 Apr; 31(4):305-8. PubMed ID: 20167399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group.
    Helbig G; Lewandowski K; Świderska A; Rodzaj M; Seferyńska I; Gajkowska-Kulik J
    Pol Arch Intern Med; 2020 Mar; 130(3):255-257. PubMed ID: 32125294
    [No Abstract]   [Full Text] [Related]  

  • 32. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
    Pardanani A; Tefferi A
    Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib].
    Wolf D; Gastl G; Rumpold H
    Dtsch Med Wochenschr; 2004 Oct; 129(40):2104-6. PubMed ID: 15455302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia.
    Fassnacht F; Roumier M; Fouret P; Levy V; Varnous S; Russel S; Lefevre G; Kahn JE
    Transplantation; 2015 Nov; 99(11):e176-7. PubMed ID: 26492057
    [No Abstract]   [Full Text] [Related]  

  • 35. FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement.
    Williams C; Kalra S; Nath U; Bown N; Wilson V; Wilkins BS; Neylon AJ
    J Clin Pathol; 2008 May; 61(5):677-80. PubMed ID: 18256119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics.
    Dahabreh IJ; Giannouli S; Zoi C; Zoi K; Voulgarelis M; Moutsopoulos HM
    Medicine (Baltimore); 2007 Nov; 86(6):344-354. PubMed ID: 18004179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib.
    Pitini V; Sturniolo G; Cavallari V; Arrigo C
    Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645
    [No Abstract]   [Full Text] [Related]  

  • 38. [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome].
    Martinaud C; Souraud JB; Cournac JM; Pons S; Ménard G; de Jaureguiberry JP; Brisou P
    Rev Med Interne; 2011 May; 32(5):e66-8. PubMed ID: 20633965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.
    Klion AD; Robyn J; Maric I; Fu W; Schmid L; Lemery S; Noel P; Law MA; Hartsell M; Talar-Williams C; Fay MP; Dunbar CE; Nutman TB
    Blood; 2007 Nov; 110(10):3552-6. PubMed ID: 17709602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pemphigus-like hypereosinophilic syndrome with FIP1L1-PDGFRA fusion gene: A challenging and uncommon clinical presentation.
    Curto-Barredo L; Segura S; Ishii N; Hashimoto T; Mascaró JM; Espinet B; Besses C; Pujol RM
    J Dermatol; 2019 Jun; 46(6):531-534. PubMed ID: 31021002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.